Atrial fibrillation reduction by renal sympathetic denervation : 12 months' results of the AFFORD study
AIM: The purpose of this pilot study was to assess whether renal sympathetic denervation (RDN) decreases atrial fibrillation (AF) burden in hypertensive patients with symptomatic AF at 6- and 12-month follow-up, as measured using an implantable cardiac monitor (ICM).
METHODS AND RESULTS: A total of 20 patients with symptomatic paroxysmal or persistent AF (EHRA ≥ II) and primary hypertension with a mean office systolic blood pressure (BP) of > 140 mmHg were enrolled. After enrolment, an ICM was implanted 3 months pre-RDN to monitor AF burden. Quality of life (QOL) was assessed using the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire. Mean age was 64 ± 7 years and 55% were females. AF burden in min/day decreased from a median (IQR) of 1.39 (0-11) pre-RDN to 0.67 (0-31.6) at 6 months (p = 0.64) and to 0.94 (0-6.0) at 12 months (pre-RDN vs. 12 months; p = 0.03). QOL improved significantly at both 6 months (+ 11 ± 15 points, p = 0.006) and 12 months (+ 10 ± 19, p = 0.04) as compared to pre-RDN. Office BP decreased significantly at 12-month follow-up (- 20 ± 19/- 7 ± 10 mmHg), p < 0.01) as compared to pre-RDN. Ambulatory BP decreased - 7 ± 16/- 3 ± 9 mmHg (p > 0.05) at 12-month follow-up as compared to pre-RDN.
CONCLUSION: This pilot study suggests that RDN might be able to decrease AF burden in min/day as measured using an ICM, with a positive effect on QOL. Large-scale randomized trials are needed to prove the definite value of RDN in hypertensive patients with atrial fibrillation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
Clinical research in cardiology : official journal of the German Cardiac Society - 108(2019), 6 vom: 09. Juni, Seite 634-642 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Feyz, Lida [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AF |
|---|
| Anmerkungen: |
Date Completed 19.12.2019 Date Revised 25.02.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00392-018-1391-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM290465354 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM290465354 | ||
| 003 | DE-627 | ||
| 005 | 20231225064807.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00392-018-1391-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0968.xml |
| 035 | |a (DE-627)NLM290465354 | ||
| 035 | |a (NLM)30413869 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Feyz, Lida |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Atrial fibrillation reduction by renal sympathetic denervation |b 12 months' results of the AFFORD study |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.12.2019 | ||
| 500 | |a Date Revised 25.02.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: The purpose of this pilot study was to assess whether renal sympathetic denervation (RDN) decreases atrial fibrillation (AF) burden in hypertensive patients with symptomatic AF at 6- and 12-month follow-up, as measured using an implantable cardiac monitor (ICM) | ||
| 520 | |a METHODS AND RESULTS: A total of 20 patients with symptomatic paroxysmal or persistent AF (EHRA ≥ II) and primary hypertension with a mean office systolic blood pressure (BP) of > 140 mmHg were enrolled. After enrolment, an ICM was implanted 3 months pre-RDN to monitor AF burden. Quality of life (QOL) was assessed using the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire. Mean age was 64 ± 7 years and 55% were females. AF burden in min/day decreased from a median (IQR) of 1.39 (0-11) pre-RDN to 0.67 (0-31.6) at 6 months (p = 0.64) and to 0.94 (0-6.0) at 12 months (pre-RDN vs. 12 months; p = 0.03). QOL improved significantly at both 6 months (+ 11 ± 15 points, p = 0.006) and 12 months (+ 10 ± 19, p = 0.04) as compared to pre-RDN. Office BP decreased significantly at 12-month follow-up (- 20 ± 19/- 7 ± 10 mmHg), p < 0.01) as compared to pre-RDN. Ambulatory BP decreased - 7 ± 16/- 3 ± 9 mmHg (p > 0.05) at 12-month follow-up as compared to pre-RDN | ||
| 520 | |a CONCLUSION: This pilot study suggests that RDN might be able to decrease AF burden in min/day as measured using an ICM, with a positive effect on QOL. Large-scale randomized trials are needed to prove the definite value of RDN in hypertensive patients with atrial fibrillation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AF | |
| 650 | 4 | |a Atrial fibrillation | |
| 650 | 4 | |a Implantable cardiac monitor | |
| 650 | 4 | |a Quality of life | |
| 650 | 4 | |a RDN | |
| 650 | 4 | |a Renal sympathetic denervation | |
| 700 | 1 | |a Theuns, Dominic A |e verfasserin |4 aut | |
| 700 | 1 | |a Bhagwandien, Rohit |e verfasserin |4 aut | |
| 700 | 1 | |a Strachinaru, Mihai |e verfasserin |4 aut | |
| 700 | 1 | |a Kardys, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Van Mieghem, Nicolas M |e verfasserin |4 aut | |
| 700 | 1 | |a Daemen, Joost |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical research in cardiology : official journal of the German Cardiac Society |d 2006 |g 108(2019), 6 vom: 09. Juni, Seite 634-642 |w (DE-627)NLM161855350 |x 1861-0692 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2019 |g number:6 |g day:09 |g month:06 |g pages:634-642 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00392-018-1391-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2019 |e 6 |b 09 |c 06 |h 634-642 | ||